Beijing QL Biopharmaceutical

Peptide therapeutics

Privately held: no public share price · China

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
GLP-1 receptorPeptide
Obesity
Phase 2
GLP-1 receptorPeptide
Obesity
Phase 1
FGF21/GLP-1 receptor (dual)Peptide
MASH / NASH

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
ZT006Phase 2Overweight , Obesity
Est. primary completion 2026-12-12 · NCT07230132 · CT.gov ↗
What to watch
2027 (1)
May 2027 (1)
zovaglutidePhase 3Overweight , Obesity
Est. primary completion 2027-05-29 · NCT07230119 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
zovaglutidePhase 2Obesity
Est. primary completion 2028-01-13 · NCT07812597 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 April 2026Topline resultzovaglutideZovaglutide (ZT002) Phase 2 in obesity: up to 13.8% weight loss at Week 24 (160 mg every 4 weeks)
Beijing QL Biopharmaceutical Co., Ltd. · Source ↗

Financial reports

No financial reports recorded.